Fondation Ophtalmologique Adolphe de Rothschild

for.paris

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

313

Active

82

Phase 3

11

Total enrollment

56,416

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Cangrelor1
Bevacizumab1
glenzocimab1
Ocrelizumab Injection [Ocrevus]1
immediate treatment with corticosteroids1
addition of rituximab if recurrence1
Subconjunctival injection of 1 mL with 5 million allogeneic BM-MSCs; one repeat within 21 days.1
Daily infusion of dornase alfa1
Probenecid1
etanercept and repeated contrast ultrasound1
blood sample2
Atropine 0.05% eyedrops1
Sampling of blood, frozen resected tissues, and cerebrospinal fluid1

Next readouts

  • 2026-02
  • 2026-03
  • 2026-12
  • 2027-02-21
  • 2028-01-15
  • 2028-03
  • 2028-06
  • 2028-06
  • 2029-02
  • 2029-09

Top conditions

  • Multiple Sclerosis16
  • Epilepsy9
  • Optic Neuritis7
  • Stroke7
  • Cataract7
  • Ischemic Stroke7
  • Acute Stroke5
  • Myopia5

Frequently asked questions about Fondation Ophtalmologique Adolphe de Rothschild

How many clinical trials does Fondation Ophtalmologique Adolphe de Rothschild have on ClinicalTrials.gov?
Fondation Ophtalmologique Adolphe de Rothschild is listed as the lead sponsor on 313 clinical trials in ClinicalTrials.gov, 82 of which are currently active (recruiting, enrolling, or ongoing).
How many of Fondation Ophtalmologique Adolphe de Rothschild's trials are in Phase 3?
11 of Fondation Ophtalmologique Adolphe de Rothschild's trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does Fondation Ophtalmologique Adolphe de Rothschild focus on?
Fondation Ophtalmologique Adolphe de Rothschild's most-studied conditions on ClinicalTrials.gov are Multiple Sclerosis, Epilepsy, Optic Neuritis, Stroke, Cataract.
When are Fondation Ophtalmologique Adolphe de Rothschild's next clinical trial readouts?
Fondation Ophtalmologique Adolphe de Rothschild has 10 upcoming primary-completion readouts tracked here; the soonest is “Myopia Control in Children: Comparison of Defocus Incorporated Multiple Segments® Lenses Versus Atropine 0.05% Eyedrops”, expected around 2026-02.